Malignancy and the skeleton

Hormone and Metabolic Research

Volumn 29, Issue 3, 1997, Pages 120-127

  Mundy, G R ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

bone; cancer; hypercalcemia

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CLODRONIC ACID; GALLIUM NITRATE; INDOMETACIN; MITHRAMYCIN; PAMIDRONIC ACID;

BONE METASTASIS; BONE PAIN; COMORBIDITY; CONFERENCE PAPER; DIURESIS; HUMAN; HYPERCALCEMIA; INTRAVENOUS DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0030912517     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-979004     Document Type: Conference Paper

References (56)

1. Mundy GR, Bertolini DR: Bone destruction and hypercalcemia in plasma cell myeloma. Seminars in Oncology 13: 291-299 (1986).
2. Mundy GR, Cove DH, Fisken R: Primary hyperparathyroidism: Changes in the pattern of clinical presentation. Lancet 1: 1317-1320 (1980).
3. Galasko CSB: Skeletal Metastases. Clin Orthop September: 18-30 (1986a).
4. Galasko CSB: Skeletal Metastases. Butterworth & Co., London (1986b), 1-160.
5. Batson OV: The function of the vertebral veins and their role in the spread of metastases. Ann Surg 112: 138-149 (1940).
6. Coman DR, De Long RP: The role of the vertebral venous system in the metastasis of cancer to the spinal column; experiments with tumour cell suspension in rats and rabbits. Cancer 4: 610-618 (1951).
7. van den Brenk HAS, Burch WM, Kelley H, Orton C: Venous diversion trapping and growth of blood-borne cancer cells en route to the lungs. Br J Cancer 31: 46-61 (1975).
8. Dodds PR, Caride VJ, Lytton B: The role of vertebral veins in the dissemination of prostatic carcinoma. J Urol 126: 753-755 (1981).
9. Eilon G, Mundy GR: Direct resorption of bone by human breast cancer cells in vitro. Nature 276: 726-728 (1978).
10. Boyde A, Maconnachie E, Reid SA, Delling G, Mundy GR: Scanning electron microscopy in bone pathology: Review of methods. Potential and applications. Scanning Electron Microscopy IV: 1537-1554 (1986).
11. c-src expression of osteoclasts to form ruffled borders and resorb bone. J Clin Invest 90: 1622-1627 (1992).
12. Tuttle KR, Kunau RT, Loveridge N, Mundy GR: Altered-renal calcium handling in hypercalcemia of malignancy. J Amer Soc Nephrol 2: 191-199 (1991).
13. Moseley JM, Kubota M, Diefenbach-Jagger H, Wettenhall REH, Kemp BE, Suva LJ, Rodda CP, Ebeling PR, Hudson PJ, Zajac JD, Martin TJ: Parathyroid hormone-related protein purified from a human lung cancer cell line. Proc Natl Acad Sci 84: 5048-5052 (1987).
14. Stewart AF, Wu T, Goumas D, Burtis WJ, Broadus AE: N-terminal amino acid sequence of two novel tumor-derived adenylate cyclase-stimulating proteins: identification of prathyroid hormone-like and parathyroid hormone-unlike domains. Biochem Biophys Res Commun 146: 672-678 (1987).
15. Strewler GJ, Stern PH, Jacobs JW, Eveloff J, Klein RF, Leung SC, Rosenblatt M, Nissenson RA: Parathyroid hormone-like protein from human renal carcinoma cells: structural and functional homology with parathyroid hormone. J Clin Invest 80: 1803-1807 (1987).
16. Motokura T, Fukumoto S, Matsumoto T, Takahashi S, Fujita A, Yamashita T, Igarashi T, Ogata E: Parathyroid hormone related protein in adult T-cell leukemia-lymphoma. Ann Intern Med 111: 484-488 (1989).
17. Yates AJP, Gutierrez GE, Smolens P, Travis PS, Katz MS, Aufdemorte TB, Boyce BF, Hymer TK, Poser JW, Mundy GR: Effects of a synthetic peptide of a parathyroid hormone-related protein on calcium homeostasis, renal tubular calcium reabsorption and bone metabolism. J Clin Invest 81: 932-938 (1988).
18. Kukreja SC, Shevrin DH, Wimbiscus SA, Ebeling PR, Danks JA, Rodda CP, Wood WI, Martin TJ: Antibodies to parathyroid hormone-related protein lower serum calcium in athymic mouse models of malignancy-associated hypercalcemia due to human tumors. J Clin Invest 82: 1798-1802 (1988).
19. Powell GJ, Southby J, Danks JA, Stillwell RG, Hayman JA, Henderson MA, Bennett RC, Martin TJ: Localization of parathyroid hormone-related protein in breast cancer metastases: increased incidence in bone compared with other sites. Cancer Res 51: 3059-3061 (1991).
20. Budayr AA, Halloran BP, King JC, Diep D, Nissenson RA, Strewler GJ: High levels of a parathyroid hormone-like protein in milk. Proc. Natl Acad Sci 86: 7183-7185 (1989)
21. Henderson B, Pettipher ER: Arthritogenic actions of recombinant IL-1 and tumour necrosis factor alpha in the rabbit: evidence for synergistic interactions between cytokines in vivo. Clin Exp Immunol 75: 306-310 (1989).
22. Guise TA, Chirgwin JM, Favarato G, Boyce BF, Mundy GR: Chinese hamster ovarian cells transfected with human parathyroid hormone-related protein cDNA cause hypercalcemia in nude mice. Lab Invest 67: 477-485 (1992).
23. Yates AJP, Favarato G, Aufdemorte TB, Marcelli C, Kester MB, Walker R, Langton BC, Bonewald L, Mundy GR: Expression of human transforming growth factor α by Chinese hamster ovarian tumors in nude mice causes hypercalcemia and increase osteoclastic bone resorption. J Bone Min Res 7: 847-853 (1992).
24. Sato K, Fujii Y, Kasono K, Ozawa M, Imamura H, Kanaji Y, Kurosawa HI, Tsushima TG, Shizume K: Parathyroid hormone-related protein and interleukin-1α synergistically stimulate bone resorption in vitro and increase the serum calcium concentration in mice in vivo. Endocrinology 124: 2172-2178 (1989).
25. Thiede MA, Rodan GA: Expression of a calcium-mobilizing parathyroid hormone-like peptide in lactating mammary tissue. Science 242: 278 (1988).
26. Rodda CP, Kubota M, Heath JA, Ebeling PR, Moseley JM, Care AD, Caple IW, Martin TJ: Evidence for a novel parathyroid hormoone-related protein in fetal lamb parathyroid glands and sheep placenta: Comparisons with a similar protein implicated in humoral hypercalcemia of malignancy. J Endocrinol 117: 261-271 (1988).
27. Bruns DE, Ferguson JE, Weir EC, Burtis WJ, Martin TJ, Bruns ME: Parathyroid hormone-related protein (PTH-rP): a novel hormone in human pregnancy. J Bone Min Res 7 (Suppl 1): 6 (1992).
28. Karaplis AC, Tybulewicz V, Mulligain RC, Kronenberg HM: Disruption of parathyroid hormone-related peptide gene leads to a multitude of skeletal abnormalities and perinatal mortality. J Bone Min Res 7 (Suppl 1): 1 (1992).
29. Yoshimoto K, Yamasaki R, Sakai H, Tezuka U, Takahashi M, Iizuka M, Sekiya T, Saito S: Ectopic production of parathyroid hormone by small cell lung cancer in a patient with hypercalcemia. J Clin Endocrinol Metab 68: 976-981 (1989).
30. Strewler GJ, Stern PH, Jacobs JW, Eveloff J, Klein RF, Leung SC, Rosenblatt M, Nissenson RA: Parathyroid hormone-like protein from human renal carcinoma cells: structural and functional homology with parathyroid hormone. J Clin Invest 80: 1803-1807 (1987).
31. Nussbaum SR, Gaz RD, Arnold A: Hypercalcemia and ectopic secretion of parathyroid hormone by an ovarian carcinoma with rearrangement of the gene for parathyroid hormone. N Engl J Med 323: 1324-1328 (1990).
32. Simpson EL, Mundy GR, D'Souza SM, Ibbotson KJ, Bockman R, Jacobs JW: Absence of parathyroid hormone messenger RNA in non-parathyroid tumors associated with hypercalcemia. New Engl J Med 309: 325-330 (1983).
33. Mundy GR: Calcium Homeostasis: Hypercalcemia and hypocalcemia, Martin Dunitz, United Kingdom (1990), pp 1-272.
34. Hauschka PV, Mavrakos AE, Iafrati MD, Doleman SE, Klagsbrun M: Growth factors in bone matrix. J Biol Chem 261: 12665-12674 (1986).
35. Zakalik D, Diep D, Hooks MA, Nissenson RA, Strewler GJ: Transforming growth factor beta increases stability of parathyroid hormone related protein messenger RNA. J Bone Min Res 7 (Suppl 1): 104 (1992).
36. Fidler IJ, Poste G: The cellular heterogeneity of malignant neoplasms: Implications for adjuvant chemotherapy. Sem Oncol 12: 207-221 (1985).
37. Arguello F, Baggs RB, Frantz CN: A murine model of experimental metastasis to bone and bone marrow. Cancer Res 48: 6876-6881 (1988).
38. Nakai M, Mundy GR, Williams PJ, Boyce B, Yoneda T: A synthetic antagonist to laminin inhibits the formation of osteolytic metastases by human melanoma cells in nude mice. Cancer Res 52: 5395-5399 (1992).
39. -1277 (1982).
40. Fleisch H, Russell RGG, Francis MD: Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science 165: 1262-1264 (1969).
41. Francis MD, Russell RGG, Fleisch H: Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo. Science 165: 1264-1266 (1969).
42. Russell RGG, Muhlbauer RC, Bisaz S, Williams DA, Fleisch H: The influence of pyrophosphate, condensed phosphates phosphonates, and other phosphate compounds on the dissolution of hydroxyapatite in vitro and on bone resorption induced by parathyroid hormone in tissue culture and in thyroparathyroidectomized rats. Calcif Tissue Res 6: 183-196 (1970).
43. Frijlink WB, Bijvoet OLM, te Velde J, Heynen G: Treatment of Paget's disease with (3′-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (APD). Lancet i: 799-803 (1979).
44. Meunier PJ, Chapuy MC, Alexandre C: Effects of disodium dichloromethylene diphosphonate on Paget's disease of bone. Lancet ii: 489-492 (1979).
45. Sleeboom HP, Bijvoet OLM, van Oosterom AT, Gleed JH, O'Riordan JL: Comparison of intravenous (3′-amino-1-hydroxypropylidene)-1, 1-bisphosphonate and volume repletion in tumour-induced hypercalcemia. Lancet ii: 239-243 (1983).
46. Yates AJP, Murray RM, Jerums GJ, Martin TJ: A comparison of single and multiple intravenous infusions of 3-amino-hydroxypropylidene-1, 1-bisphosphonate (APD) in the treatment of hypercalcemia of malignancy. Aust NZ J Med 17: 387-391 (1987).
47. Thiebaud D, Jaeger PH, Jacquet AF, Burckhardt P: Dose response in the treatment of hypercalaemia of malignancy by a single infusion of the bisphosphonate AHPrBP (APD). J Clin Oncol 6: 762-768 (1988).
48. Portmann L, Haefliger JM, Bill G, Burckhardt P: Un traitement simple de l'hypercalcemie tumorale: 1′-amino-hydroxypropylidene bisphosphonate (APD). iv Schweiz Med Wochenschr 51: 1960-1963 (1983).
49. Body JJ, Borkowski A, Cleeren A, Bijvoet OL: Treatment of malignancy-associated hypercalcemia with intravenous aminohydroxypropylidene diphosphonate. J Clin Oncol 8: 1177-1183 (1986).
50. Body JJ, Pot M, Borkowski A, Sculier JP, Klastersky J: Dose-response study of aminohydroxypropylidene bisphosphonate in tumor-associated hypercalcemia. Am J Medicine 82: 957-963 (1987).
51. Coleman RE, Rubens RD: 3(amino-1, 1-hydroxypropylidene) bisphosphonate (APD) for hypercalcemia of breast cancer. Brit J Cancer 56: 465-469 (1987).
52. Ralston SH, Alzaid AA, Gardner MD, Boyle IT: Treatment of cancer associated hypercalcemia with combined aminohydroxypropylidene diphosphonate and calcitonin. Brit Med J 292: 1549-1550 (1986).
53. Binstock ML, Mundy GR: Effect of calcitonin and glucocorticoids in combination in malignant hypercalcemia. Ann Intern Med 93: 269-272 (1980).
54. Au WYW: Calcitonin treatment of hypercalcemia due to parathyroid carcinoma - synergistic effect of prednisone on long-term treatment of hypercalcemia. Arch Intern Med 135: 1594-1597 (1975).
55. Hosking DJ, Bijvoet OLM: Therapeutic uses of calcitonin. In: Endocrinology of Calcium Metabolism. Parsons JA (ed) Raven Press, New York (1982), pp 485-535.
56. Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff G, Wheeler H, Simeone JF, Seaman J, Knight RD, Heffernan M, Rietsma D: Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. New Engl J Med 335: 1785-1791 (1996).